Yale University

New Haven, Connecticut
Sterling Professor of Chemistry

Research

Dr. Jorgensen’s research focuses on the discovery of drugs for cancer chemotherapy. He is a renowned expert in developing and applying the requisite methodology and computer software for computer-aided drug design. His team of experts are designing drugs that bind tightly to enzymes (protein molecules that catalyze reactions) involved in aberrant cell proliferation. The tight binding causes the enzymes to stop functioning, the cancer cells to stop reproducing, and the tumors to shrink. Such drugs are called enzyme inhibitors. Specifically, his research has sought inhibitors of an enzyme called fibroblast growth factor receptor 1 kinase (FGFR1 kinase). Aberrant FGFR kinase activity has been implicated in numerous cancers including breast cancer, human pancreatic cancer, astrocytomas, salivary gland adenosarcoma, Kaposi’s sarcoma, ovarian cancer, and prostate cancer. Therefore, discovery of inhibitors of FGFR1 kinase has substantial potential therapeutic value.

His team computationally modeled millions of compounds that might be possible FGFR1 kinase inhibitors and 23 compounds were purchased and experimentally tested. Two of the compounds showed some inhibitory activity towards FGFR1 kinase and his team focused on improving the potency of the compounds and their chemical properties to make them more likely to become drugs. Their work required the preparation (“synthesis”) of modified versions, “analogs”, of the initial “lead” compounds. They explored various changes in the series of thienopyrimidinone compounds and simplified the structures to only pyrimidinones which are uncommon as kinase inhibitors and were active at low micromolar concentrations. Future research will focus on enhancing the activity of these compounds and testing for selectivity in inhibiting other kinases.

Bio

Dr. William Jorgensen received his B.A. from Princeton University and his Ph.D. from Harvard University. In 1975, he first joined the faculty at Purdue University and in 1990, he joined the faculty at Yale University as the Whitehead Professor of Chemistry. He served as Director, Division of Physical Sciences & Engineering and he is currently the Sterling Professor of Chemistry.

From 2005 to 2010 at Yale University, Dr. Jorgensen co-directed the NFCR Center for Anti-Cancer Drug Design and Discovery with Director and NFCR-supported scientist, Dr. Alanna Schepartz. He is an elected member of the National Academy of Sciences and a Fellow of the American Chemical Society. Dr. Jorgensen is the recipient of numerous awards including; the ACS Award for Computers in Chemical and Pharmaceutical Research; Award in Computational Biology – International Society for Quantum Biology and Pharmacology; the Hildebrand Award in the Theoretical and Experimental Chemistry of Liquids (ACS); and the Tetraheron Prize.

He has published over 400 articles in the field of computational chemistry. He and his lab have developed software and computer modeling programs for drug design including TIP3P and TIP4P water models, the OPLS force field, and on free-energy perturbation theory for modeling reactions and molecular recognition in solution. Dr. Jorgensen’s service to the community includes numerous advisory boards in government and industry and journal editorial boards. He has been the Editor of the ACS Journal of Chemical Theory and Computation since its founding in 2005.

Related Content

Newly Diagnosed Brain Tumor Patients Should Consult Their Doctors Before Starting the Preventive Anti-Epileptic Treatment

Bone Cancer 101

New Brain Scan Technology Can Improve Tumor Removal

Any illness or disease that impacts the brain is highly complex. None more so than brain tumors, which affect over 20,000 Americans each year. While surgeons have become more advanced in the removal of brain tumors, experts continue to face extreme challenges in ensuring all cancerous tissues are removed during surgery. That is, until now.  A recent study found a high-intensity focused ultrasound 2.5 times more effective at identifying cancerous tissue than surgeons alone and significantly better than traditional ultrasound. The newly identified ultrasound cancer treatment technique is referred to as shear wave elastography.  Shear wave elastography measures the stiffness and stretch within the tissue, with vibrations moving faster through stiffer tissue. Brain tumors tend to be stiffer than normal brain tissue, allowing the new method to map suspicious areas of particular stiffness. In the study, researchers compared this high-intensity focused ultrasound to the standard ultrasound cancer treatment and a surgeon’s opinion regarding which tissues to remove.  The study used these three different techniques on a total of 26 patients. All of the techniques were compared with gold-standard MRI scans after the surgery – which while effective, are exceptionally time-consuming and expensive.  While the shear wave elastography ultrasound cancer treatment proved to be the most effective with 94% sensitivity (compared to 73% for the standard ultrasound tumor removal and 36% for the surgeon’s opinion), researchers concluded that the shear wave scans may yield more false positives than surgeons.  Ensuring all of a brain tumor is removed without damaging healthy tissue is a major challenge in brain surgery. This new type of scan can greatly increase a surgeon’s confidence that no cancer tissue is left behind in surgery.  The use of this unique ultrasound in cancer treatment makes a significant stride towards improving the health outlook for brain cancer patients. The National Foundation for Cancer Research (NFCR) is also providing new hope in the realm of brain cancer through its partnership with Global Coalition for Adaptive Research (GCAR). GCAR is a nonprofit organization comprised of some of the world’s foremost physicians, clinical researchers and investigators united in expediting the discovery and development of cures for patients with rare and deadly diseases. GCAR is the official sponsor of GBM AGILE, an adaptive platform trial for patients with glioblastoma (GBM) – the most common and deadliest of malignant primary brain tumors. The GBM AGILE has been developed with a revolutionary approach to defeating GBM, with the goal of enabling faster and more efficient testing of new agents and combination therapies, better identification of predictive and prognostic biomarkers and delivery of more effective treatments to all glioblastoma patients. GBM AGILE is an innovative approach for treating brain cancer, providing new hope where little existed before. NFCR continues to fund innovative researchers paving the way to finding new screening methods, treatments, and cures for all cancers, including brain cancer. To learn more about the progress that NFCR-funded scientists are making in the way of brain cancer, visit the NFCR Brain Cancer page.  Additional Reads You May Enjoy: “Pink Drink” to Aid Brain Tumor Treatment Treating Brain Cancer: What You Need to Know GBM AGILE – Changing the Way We Fight Brain Cancer Stay connected with us! […]